Leios Therapeutics Signs Exclusive License and Investment Deal with China Medical System for 10XB-101
Leios Therapeutics signs exclusive licensing agreement and strategic investment deal with China Medical System Holdings for 10XB-101, a novel injectable for focal fat reduction.
Key points
- Leios Therapeutics licenses 10XB-101 fat-reduction injectable to China Medical System with strategic investment.
- 10XB-101 targets Asian medical aesthetics market as novel best-in-class body contouring candidate.
- Phase 2/3 clinical data and NMPA filing timeline are key forward milestones for the deal value.
What’s your take on this? Join the discussion below.
Read the full analysis on market.news
🇭🇰 Hong Kong Stocks M&A pharma biotech healthcare asia mergers